Compare Stocks: LEXX, COCP, QNTM, and CLRB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLRB Cellectar Biosciences	$2.38 -0.8%	$2.50	$2.20 ▼ $6.52	$22.50M	0.56	34,798 shs	73,554 shs
COCP Cocrystal Pharma	$1.18 +3.9%	$1.06	$0.76 ▼ $2.03	$23.31M	1.48	45,526 shs	176,481 shs
LEXX Lexaria Bioscience	$3.24 -1.5%	$8.25	$2.80 ▼ $23.25	$5.35M	0.5	120,466 shs	76,320 shs
QNTM Quantum Biopharma	$3.66 -1.6%	$3.25	$2.07 ▼ $21.00	$23.42M	0.45	144,261 shs	95,046 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLRB Cellectar Biosciences	0.00%	+3.03%	-8.11%	-14.70%	-52.96%
COCP Cocrystal Pharma	0.00%	-4.52%	+1.20%	+18.99%	-2.55%
LEXX Lexaria Bioscience	0.00%	-18.39%	-71.25%	-60.01%	-82.15%
QNTM Quantum Biopharma	0.00%	+14.38%	+6.40%	-3.68%	-79.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLRB Cellectar Biosciences	$2.38 -0.8%	$2.50	$2.20 ▼ $6.52	$22.50M	0.56	34,798 shs	73,554 shs
COCP Cocrystal Pharma	$1.18 +3.9%	$1.06	$0.76 ▼ $2.03	$23.31M	1.48	45,526 shs	176,481 shs
LEXX Lexaria Bioscience	$3.24 -1.5%	$8.25	$2.80 ▼ $23.25	$5.35M	0.5	120,466 shs	76,320 shs
QNTM Quantum Biopharma	$3.66 -1.6%	$3.25	$2.07 ▼ $21.00	$23.42M	0.45	144,261 shs	95,046 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLRB Cellectar Biosciences	0.00%	+3.03%	-8.11%	-14.70%	-52.96%
COCP Cocrystal Pharma	0.00%	-4.52%	+1.20%	+18.99%	-2.55%
LEXX Lexaria Bioscience	0.00%	-18.39%	-71.25%	-60.01%	-82.15%
QNTM Quantum Biopharma	0.00%	+14.38%	+6.40%	-3.68%	-79.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLRB Cellectar Biosciences	2.80	Moderate Buy	$11.00	362.18% Upside
COCP Cocrystal Pharma	1.00	Sell	N/A	N/A
LEXX Lexaria Bioscience	2.00	Hold	$22.50	594.44% Upside
QNTM Quantum Biopharma	2.00	Hold	$8.00	118.58% Upside

Current Analyst Ratings Breakdown

Latest LEXX, COCP, QNTM, and CLRB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	LEXX Lexaria Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/31/2026	QNTM Quantum Biopharma	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
8/21/2026	COCP Cocrystal Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/21/2026	QNTM Quantum Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/24/2026	LEXX Lexaria Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	CLRB Cellectar Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	LEXX Lexaria Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/12/2026	CLRB Cellectar Biosciences	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/25/2026	LEXX Lexaria Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$1.89 per share	N/A
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	$0.46 per share	N/A
LEXX Lexaria Bioscience	$710K	7.53	N/A	N/A	$2.00 per share	1.62
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$1.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLRB Cellectar Biosciences	-$21.79M	-$3.84	N/A	N/A	N/A	N/A	-185.35%	-115.42%	10/29/2026 (Estimated)
COCP Cocrystal Pharma	-$8.83M	-$0.76	N/A	N/A	N/A	N/A	-207.47%	-123.33%	11/13/2026 (Estimated)
LEXX Lexaria Bioscience	-$11.90M	-$5.10	N/A	N/A	N/A	N/A	-174.93%	-143.89%	10/28/2026 (Estimated)
QNTM Quantum Biopharma	-$26.17M	-$5.49	N/A	N/A	N/A	N/A	-582.23%	-184.20%	11/6/2026 (Estimated)

Latest LEXX, COCP, QNTM, and CLRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CLRB Cellectar Biosciences	-$0.52	-$0.57	-$0.05	-$0.57	$12.00 million	N/A
8/13/2026	Q2 2026	COCP Cocrystal Pharma	-$0.17	-$0.23	-$0.06	-$0.23	$0.11 million	$0.11 million
8/13/2026	Q2 2026	QNTM Quantum Biopharma	-$0.4116	-$0.47	-$0.0584	-$0.47	N/A	N/A
7/13/2026	Q3 2026	LEXX Lexaria Bioscience	-$0.06	-$0.08	-$0.02	-$1.20	$0.05 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	N/A
LEXX Lexaria Bioscience	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLRB Cellectar Biosciences	N/A	6.66	6.66
COCP Cocrystal Pharma	N/A	1.24	1.24
LEXX Lexaria Bioscience	N/A	10.61	10.61
QNTM Quantum Biopharma	N/A	1.20	1.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLRB Cellectar Biosciences	16.41%
COCP Cocrystal Pharma	6.72%
LEXX Lexaria Bioscience	13.06%
QNTM Quantum Biopharma	1.24%

Insider Ownership

Company	Insider Ownership
CLRB Cellectar Biosciences	2.58%
COCP Cocrystal Pharma	39.40%
LEXX Lexaria Bioscience	8.39%
QNTM Quantum Biopharma	8.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLRB Cellectar Biosciences	11	9.45 million	9.21 million	No Data
COCP Cocrystal Pharma	10	19.26 million	11.67 million	Not Optionable
LEXX Lexaria Bioscience	7	1.65 million	1.51 million	Not Optionable
QNTM Quantum Biopharma	7	6.40 million	5.85 million	N/A

LEXX, COCP, QNTM, and CLRB Headlines

Recent News About These Companies

Quantum BioPharma (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target

September 17 at 2:05 PM | markets.businessinsider.com

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

September 17 at 8:00 AM | globenewswire.com

Quantum BioPharma (QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit

September 15, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit

September 15, 2026 | markets.businessinsider.com

Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

September 15, 2026 | newsfilecorp.comN

NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research

September 14, 2026 | theglobeandmail.com

NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment' in MS Research

September 14, 2026 | globenewswire.com

Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

September 11, 2026 | globenewswire.com

Quantum BioPharma Receives FDA Clearance For Lucid-MS Phase 2 Trial

September 9, 2026 | rttnews.com

Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment

September 9, 2026 | globenewswire.com

Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange

September 1, 2026 | globenewswire.com

Quantum Biopharma Provides Corporate Update

August 21, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

August 20, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

August 20, 2026 | markets.businessinsider.com

Quantum BioPharma (QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2

August 17, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2

August 17, 2026 | usatoday.com

Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

August 14, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis

August 13, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis

August 13, 2026 | markets.businessinsider.com

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 Multiple Sclerosis Trial

August 11, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX, COCP, QNTM, and CLRB Company Descriptions

Cellectar Biosciences NASDAQ:CLRB

$2.38 -0.02 (-0.83%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.38 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Cocrystal Pharma NASDAQ:COCP

$1.18 +0.04 (+3.86%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$1.23 +0.04 (+3.46%)

As of 09/18/2026 07:38 PM Eastern

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Lexaria Bioscience NASDAQ:LEXX

$3.24 -0.05 (-1.52%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.10 -0.14 (-4.32%)

As of 09/18/2026 07:51 PM Eastern

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Quantum Biopharma NASDAQ:QNTM

$3.66 -0.06 (-1.61%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.66 0.00 (0.00%)

As of 09/18/2026 07:50 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LEXX, COCP, QNTM, and CLRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LEXX, COCP, QNTM, and CLRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LEXX, COCP, QNTM, and CLRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX, COCP, QNTM, and CLRB Company Descriptions

Cellectar Biosciences NASDAQ:CLRB

Cocrystal Pharma NASDAQ:COCP

Lexaria Bioscience NASDAQ:LEXX

Quantum Biopharma NASDAQ:QNTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LEXX, COCP, QNTM, and CLRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LEXX, COCP, QNTM, and CLRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LEXX, COCP, QNTM, and CLRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX, COCP, QNTM, and CLRB Company Descriptions

Cellectar Biosciences NASDAQ:CLRB

Cocrystal Pharma NASDAQ:COCP

Lexaria Bioscience NASDAQ:LEXX

Quantum Biopharma NASDAQ:QNTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools